

Raptor Pharmaceutical Corp
 Form 4
 September 11, 2013

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
FRANKLIN RICHARD L

 (Last) (First) (Middle)

C/O RAPTOR PHARMACEUTICAL CORP., 5 HAMILTON LANDING, SUITE 160

 (Street)

NOVATO, CA 94949

 (City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Raptor Pharmaceutical Corp [RPTP]

 3. Date of Earliest Transaction
 (Month/Day/Year)
09/09/2013

5. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)
 Director 10% Owner
 Officer (give title below) Other (specify below)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2013 ⁽¹⁾		M		10,715	A	\$ 2.02
Common Stock	09/09/2013 ⁽¹⁾		S		10,715	D	\$ 14.2402

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control

SEC 1474 (9-02)

Edgar Filing: Raptor Pharmaceutical Corp - Form 4

number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Stock options (right to buy)	\$ 2.02	09/09/2013 ⁽¹⁾		M	10,715	09/09/2010 ⁽²⁾ 03/09/2020	Common Stock 10,715
Stock options (right to buy)	\$ 2.23					07/10/2012 ⁽⁴⁾ 07/10/2018	Common Stock 34,969
Stock options (right to buy)	\$ 2.97					02/28/2011 ⁽⁵⁾ 10/12/2020	Common Stock 30,000
Stock options (right to buy)	\$ 3.54					11/22/2010 ⁽⁶⁾ 11/22/2020	Common Stock 90,000
Stock Options (right to buy)	\$ 5.13					12/22/2011 ⁽⁴⁾ 09/22/2021	Common Stock 30,000
Stock Options (right to buy)	\$ 5.13					03/22/2012 ⁽⁵⁾ 09/22/2021	Common Stock 90,000
Stock options (right to buy)	\$ 5.49					12/25/2012 ⁽⁷⁾ 09/25/2022	Common Stock 50,000

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
FRANKLIN RICHARD L C/O RAPTOR PHARMACEUTICAL CORP. 5 HAMILTON LANDING, SUITE 160 NOVATO, CA 94949	X			

Signatures

/s/ Kim R. Tsuchimoto, Raptor Pharmaceutical Corp., Attorney-in-fact	09/11/2013
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 12, 2013.
- (2) Original options vest 6/48ths on September 9, 2010 and 1/48th per month thereafter.
This transaction was executed in multiple trades at prices ranging from \$14.07 to \$14.48. The price reported above reflects the weighted
- (3) average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- (4) Fully vested and exercisable.
- (5) Stock options start vesting 6/48ths from grant date and 1/48th per month thereafter.
- (6) Stock option vests 25% immediately and 75% pro rata over 36 months.
- (7) Stock options vest 25% quarterly.
The shares listed as owned in column 9 represent the total shares for each respective option. Previous reports reflected aggregate amounts of option shares in column 9. The holding lines included on this Form 4 are included solely to correct the breakdown of shares among
- (8) various stock options and are not meant to reflect any change in beneficial ownership of option shares other than those reported as a transaction on this Form 4.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.